A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load.
第一作者:
Michael,Dougan
第一单位:
Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
作者:
主题词
抗体, 中和(Antibodies, Neutralizing);儿童(Child);人类(Humans);中年人(Middle Aged);预后(Prognosis);病毒载量(Viral Load)
DOI
10.1093/cid/ciab912
PMID
34718468
发布时间
2022-12-07
- 浏览0

Clinical infectious diseases
e440-e449页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文